

## **TWINCORE - Seminar**

Tuesday September 10<sup>th</sup>, 2019, 5 p.m. TWINCORE Lecture Hall 0020

"HCV-specific CD4 T cell immunity after cure of persistent infection – implications for HCVvaccine development"



## PD Dr. med. Tobias Böttler

Despite recent advances in the treatment of chronic HCV-infection with highly potent direct-acting antivirals (DAA), vaccine candidates for HCV-infection have so far failed to provide protection. As patients that have been cured by DAA-therapy are still susceptible to re-infection, vaccine candidates have to be developed that induce potent HCV-immunity in both HCV-naïve and HCV-experienced individuals. Thus, a detailed understanding of the HCV-specific immune response after DAA-cure is of great importance to explore in how far HCV-specific CD4 T cells may be susceptible to vaccination approaches even after years of persistent infection.

## Who is Tobias Böttler?

- Senior physician at the Clinic for Internal Medicine II, Gastroenterology and Hepatology, Medical Center - University of Freiburg since 2017.
- Group leader of a DFG funded research group since 2014.
- Grant of the Berta Ottenstein Program for Advanced Clinician Scientists 2019 - 2020.

Contact: Prof. Thomas Pietschmann